

Thomas Grunt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7133020/publications.pdf>

Version: 2024-02-01

35
papers

5,234
citations

304368

22
h-index

377514

34
g-index

36
all docs

36
docs citations

36
times ranked

12994
citing authors

#	ARTICLE	IF	CITATIONS
1	Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 14877.	1.6	13
2	Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry. <i>International Journal of Molecular Medicine</i> , 2019, 43, 47-56.	1.8	24
3	Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 688-703.	4.2	145
4	Interacting Cancer Machineries: Cell Signaling, Lipid Metabolism, and Epigenetics. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 86-98.	3.1	59
5	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 517-529.	1.0	3
6	Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. <i>Oncotarget</i> , 2018, 9, 26491-26506.	0.8	23
7	Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer. <i>Cancer Letters</i> , 2017, 388, 158-166.	3.2	15
8	Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. <i>PLoS ONE</i> , 2017, 12, e0185566.	1.1	7
9	Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 11600-11613.	0.8	43
10	Long term storage in liquid nitrogen leads to only minor phenotypic and gene expression changes in the mammary carcinoma model cell line BT474. <i>Oncotarget</i> , 2017, 8, 35076-35087.	0.8	4
11	Increased lipid desaturation and ovarian cancer stem cells. <i>Translational Cancer Research</i> , 2017, 6, S472-S475.	0.4	2
12	HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK. <i>PLoS ONE</i> , 2016, 11, e0146311.	1.1	21
13	Abstract B01: Multilevel interference with receptor-PI3K-mTORC1 signaling is key mechanism for anticancer activity of fatty acid synthase inhibitors. , 2016, , .		0
14	Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. <i>International Journal of Cancer</i> , 2015, 136, 2078-2090.	2.3	60
15	Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. <i>Cancer Genetics</i> , 2015, 208, 241-252.	0.2	84
16	Correlation of circular RNA abundance with proliferation – exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis and normal human tissues. <i>Scientific Reports</i> , 2015, 5, 8057.	1.6	653
17	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. <i>Journal of Hematology and Oncology</i> , 2015, 8, 16.	6.9	80
18	Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling. <i>Current Cancer Drug Targets</i> , 2013, 13, 188-204.	0.8	72

#	ARTICLE	IF	CITATIONS
19	The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells. <i>Cancer Letters</i> , 2012, 319, 164-172.	3.2	24
20	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
21	Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer. <i>Journal of Nucleic Acids</i> , 2012, 2012, 1-12.	0.8	69
22	Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2012, 42, 953-960.	1.7	79
23	The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 387-400.	1.1	52
24	hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7816-7827.	3.2	37
25	Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2011, 9, 1767-1779.	1.5	62
26	The role of c-FLIPL in ovarian cancer: Chaperoning tumor cells from immunosurveillance and increasing their invasive potential. <i>Gynecologic Oncology</i> , 2010, 117, 451-459.	0.6	23
27	Neoplastic stem cells: Current concepts and clinical perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 79-98.	2.0	29
28	Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2009, 385, 454-459.	1.0	77
29	Upregulation of retinoic acid receptor- β by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways. <i>Journal of Cellular Physiology</i> , 2007, 211, 803-815.	2.0	12
30	The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor- β tumor-suppressor gene in breast cancer cells. <i>Differentiation</i> , 2007, 75, 883-890.	1.0	6
31	Receptor signaling in cancer. <i>Differentiation</i> , 2007, 75, 767-769.	1.0	0
32	c-erbB-3. <i>Journal of Cell Biology</i> , 2002, 157, 929-940.	2.3	193
33	Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. <i>International Journal of Cancer</i> , 1995, 61, 649-657.	2.3	58
34	Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells. <i>International Journal of Cancer</i> , 1995, 63, 560-567.	2.3	71
35	In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. <i>Cancer</i> , 1993, 71, 3082-3090.	2.0	6